Literature DB >> 12856218

Smallpox vaccination: a review, part II. Adverse events.

Vincent A Fulginiti1, Arthur Papier, J Michael Lane, John M Neff, D A Henderson.   

Abstract

Smallpox vaccination of health care workers, military personnel, and some first responders has begun in the United States in 2002-2003 as one aspect of biopreparedness. Full understanding of the spectrum of adverse events and of their cause, frequency, identification, prevention, and treatment is imperative. This article describes known and suspected adverse events occurring after smallpox vaccination.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12856218     DOI： 10.1086/375825

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  90 in total

1.  Genome-wide genetic associations with IFNγ response to smallpox vaccine.

Authors:  Richard B Kennedy; Inna G Ovsyannikova; V Shane Pankratz; Iana H Haralambieva; Robert A Vierkant; Robert M Jacobson; Gregory A Poland
Journal:  Hum Genet       Date:  2012-06-03       Impact factor: 4.132

2.  Evaluation of therapeutic interventions for vaccinia virus keratitis.

Authors:  Sharon Altmann; Curtis R Brandt; Christopher J Murphy; Ravi Patnaikuni; Teresa Takla; Megan Toomey; Brittany Nesbit; Kimberly McIntyre; Jill Covert; Richard Dubielzig; Gary Leatherberry; Elizabeth Adkins; Shantha Kodihalli
Journal:  J Infect Dis       Date:  2011-01-28       Impact factor: 5.226

3.  Combination therapy of vaccinia virus infection with human anti-H3 and anti-B5 monoclonal antibodies in a small animal model.

Authors:  Megan M McCausland; Mohammed Rafii-El-Idrissi Benhnia; Lindsay Crickard; John Laudenslager; Steven W Granger; Tomoyuki Tahara; Ralph Kubo; Lilia Koriazova; Shinichiro Kato; Shane Crotty
Journal:  Antivir Ther       Date:  2010

4.  Development of the small-molecule antiviral ST-246 as a smallpox therapeutic.

Authors:  Douglas W Grosenbach; Robert Jordan; Dennis E Hruby
Journal:  Future Virol       Date:  2011-05       Impact factor: 1.831

5.  Vaccinia viruses with a serpin gene deletion and expressing IFN-gamma induce potent immune responses without detectable replication in vivo.

Authors:  Fatema A Legrand; Paulo H Verardi; Kenneth S Chan; Yue Peng; Leslie A Jones; Tilahun D Yilma
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-10       Impact factor: 11.205

6.  Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus.

Authors:  Zhaochun Chen; Patricia Earl; Jeffrey Americo; Inger Damon; Scott K Smith; Yi-Hua Zhou; Fujuan Yu; Andrew Sebrell; Suzanne Emerson; Gary Cohen; Roselyn J Eisenberg; Juraj Svitel; Peter Schuck; William Satterfield; Bernard Moss; Robert Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-25       Impact factor: 11.205

7.  2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings.

Authors:  Jane D Siegel; Emily Rhinehart; Marguerite Jackson; Linda Chiarello
Journal:  Am J Infect Control       Date:  2007-12       Impact factor: 2.918

8.  Protection against vaccinia virus challenge by CD8 memory T cells resolved by molecular mimicry.

Authors:  Markus Cornberg; Brian S Sheridan; Frances M Saccoccio; Michael A Brehm; Liisa K Selin
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

9.  Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: scarification vaccination.

Authors:  Garilyn M Jentarra; Michael C Heck; Jin Won Youn; Karen Kibler; Jeffrey O Langland; Carole R Baskin; Olga Ananieva; Yung Chang; Bertram L Jacobs
Journal:  Vaccine       Date:  2008-04-08       Impact factor: 3.641

10.  Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge.

Authors:  Linda S Wyatt; Patricia L Earl; Leigh Anne Eller; Bernard Moss
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-11       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.